Metabolomics profiling of visceral and abdominal subcutaneous adipose tissue in colorectal cancer patients: results from the ColoCare study

Jennifer Ose*, Andreana N. Holowatyj, Johanna Nattenmüller, Biljana Gigic, Tengda Lin, Caroline Himbert, Nina Habermann, David Achaintre, Augustin Scalbert, Pekka Keski-Rahkonen, Jürgen Böhm, Petra Schrotz-King, Martin Schneider, Alexis Ulrich, Ellen Kampman, Matty Weijenberg, Andrea Gsur, Per Magne Ueland, Hans Ulrich Kauczor, Cornelia M. Ulrich

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Purpose: Underlying mechanisms of the relationship between body fatness and colorectal cancer remain unclear. This study investigated associations of circulating metabolites with visceral (VFA), abdominal subcutaneous (SFA), and total fat area (TFA) in colorectal cancer patients. Methods: Pre-surgery plasma samples from 212 patients (stage I–IV) from the ColoCare Study were used to perform targeted metabolomics. VFA, SFA, and TFA were quantified by computed tomography scans. Partial correlation and linear regression analyses of VFA, SFA, and TFA with metabolites were computed and corrected for multiple testing. Cox proportional hazards were used to assess 2-year survival. Results: In patients with metastatic tumors, SFA and TFA were statistically significantly inversely associated with 16 glycerophospholipids (SFA: pFDR range 0.017–0.049; TFA: pFDR range 0.029–0.048), while VFA was not. Doubling of ten of the aforementioned glycerophospholipids was associated with increased risk of death in patients with metastatic tumors, but not in patients with non-metastatic tumors (phet range: 0.00044–0.049). Doubling of PC ae C34:0 was associated with ninefold increased risk of death in metastatic tumors (Hazard Ratio [HR], 9.05; 95% confidence interval [CI] 2.17–37.80); an inverse association was observed in non-metastatic tumors (HR 0.17; 95% CI 0.04–0.87; phet = 0.00044). Conclusion: These data provide initial evidence that glycerophospholipids in metastatic colorectal cancer are uniquely associated with subcutaneous adiposity, and may impact overall survival.

Original languageEnglish
Pages (from-to)723-735
JournalCancer Causes and Control
Volume31
Early online date19 May 2020
DOIs
Publication statusPublished - Aug 2020

Keywords

  • Adipose tissue
  • Colorectal cancer
  • Glycerophospholipids
  • Survival

Fingerprint Dive into the research topics of 'Metabolomics profiling of visceral and abdominal subcutaneous adipose tissue in colorectal cancer patients: results from the ColoCare study'. Together they form a unique fingerprint.

  • Cite this

    Ose, J., Holowatyj, A. N., Nattenmüller, J., Gigic, B., Lin, T., Himbert, C., Habermann, N., Achaintre, D., Scalbert, A., Keski-Rahkonen, P., Böhm, J., Schrotz-King, P., Schneider, M., Ulrich, A., Kampman, E., Weijenberg, M., Gsur, A., Ueland, P. M., Kauczor, H. U., & Ulrich, C. M. (2020). Metabolomics profiling of visceral and abdominal subcutaneous adipose tissue in colorectal cancer patients: results from the ColoCare study. Cancer Causes and Control, 31, 723-735. https://doi.org/10.1007/s10552-020-01312-1